Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety evaluation of intravenous Epoetin STADA for maintenance treatment of renal anemia in chronic hemodialysis patients (open follow-up)
2004-004401-26Phase 3Completed
- Sponsor
- STADA Arzneimittel AG
- Start
- Dec 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epoetin zeta in anemia due to end-stage renal disease, sponsored by STADA Arzneimittel AG. Primary endpoint: Safety (adverse events). Started Dec 2004; status: completed.
02
Drugs
epoetin zeta
03
Conditions
anemia due to end-stage renal disease
Beyond the preview
Go deeper on 2004-004401-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004401-26.